Therapeutic equivalence of a low dose artemisinin formulation in falciparum malaria patients.
We have evaluated the therapeutic equivalence of a beta-cyclodextrin-artemisinin complex at an artemisinin dose of 150 mg, with a commercial reference preparation, Artemisinin 250 at a recommended dose of 250 mg. One hundred uncomplicated falciparum malarial patients were randomly assigned to orally receive either beta-cyclodextrin-artemisinin complex (containing 150 mg artemisinin) twice daily for five days or the active comparator (containing 250 mg artemisinin) twice daily for five days. The patients were hospitalized for seven days and were required to attend follow up assessments on days 14, 21, 28 and 35. All patients in both treatment groups were cured of the infection and achieved therapeutic success. At day seven of treatment, all patient blood was clear of the parasites and the sublingual temperature of all patients was less than 37.5 degrees C. Moreover, the parasite clearance time in both treatment groups was similar, being approximately three days after initiation of treatment. Comparable plasma artemisinin concentrations were observed between patients in both treatment groups at 1.5 and 3.0 h, although slightly higher levels were obtained with patients in the beta-cyclodextrin-artemisinin complex-treated group. The beta-cyclodextrin-artemisinin complex at a dose of 150 mg artemisinin was therapeutically equivalent to 250 mg Artemisinin 250. Additionally, patients receiving beta-cyclodextrin-artemisinin complex showed less variability in their plasma artemisinin concentrations at 1.5 h post-dosing, which suggested a more consistent rate of drug absorption.
Wong
J W
JW
School of Pharmaceutical Sciences, University of Science Malaysia, Penang, Malaysia.
Yuen
K H
KH
Nagappan
S
S
Shahul
W S
WS
Ho
S S David
SS
Gan
E K
EK
Toh
W T
WT
D000293:Adolescent; D000328:Adult; D000818:Animals; D037621:Artemisinins / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003505:Cyclodextrins / Q000493:pharmacokinetics; D005260:Female; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010963:Plasmodium falciparum / Q000187:drug effects; D012717:Sesquiterpenes / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D013810:Therapeutic Equivalency; D016896:Treatment Outcome; D047392:beta-Cyclodextrins
D037621:Artemisinins; D003505:Cyclodextrins; D012717:Sesquiterpenes; D047392:beta-Cyclodextrins; C031327:artemisinin; C031215:betadex